Cargando…

Using Molecular Transmission Networks to Reveal the Epidemic of Pretreatment HIV-1 Drug Resistance in Guangxi, China

INTRODUCTION: Pretreatment drug resistance (PDR) is becoming an obstacle to the success of ART. This study investigated the prevalence of PDR and the transmission clusters (TCs) of drug resistance mutations (DRMs) in two cities where drug abuse used to be high to describe the local HIV-1 transmissio...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Fei, Liang, Bingyu, Liang, Xu, Lin, Zhaosen, Yang, Yuan, Liang, Na, Yang, Yao, Liang, Huayue, Jiang, Jiaxiao, Huang, Jiegang, Huang, Rongye, Zhong, Shanmei, Qin, Cai, Jiang, Junjun, Ye, Li, Liang, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460771/
https://www.ncbi.nlm.nih.gov/pubmed/34567064
http://dx.doi.org/10.3389/fgene.2021.688292
_version_ 1784571826783911936
author Zhang, Fei
Liang, Bingyu
Liang, Xu
Lin, Zhaosen
Yang, Yuan
Liang, Na
Yang, Yao
Liang, Huayue
Jiang, Jiaxiao
Huang, Jiegang
Huang, Rongye
Zhong, Shanmei
Qin, Cai
Jiang, Junjun
Ye, Li
Liang, Hao
author_facet Zhang, Fei
Liang, Bingyu
Liang, Xu
Lin, Zhaosen
Yang, Yuan
Liang, Na
Yang, Yao
Liang, Huayue
Jiang, Jiaxiao
Huang, Jiegang
Huang, Rongye
Zhong, Shanmei
Qin, Cai
Jiang, Junjun
Ye, Li
Liang, Hao
author_sort Zhang, Fei
collection PubMed
description INTRODUCTION: Pretreatment drug resistance (PDR) is becoming an obstacle to the success of ART. This study investigated the prevalence of PDR and the transmission clusters (TCs) of drug resistance mutations (DRMs) in two cities where drug abuse used to be high to describe the local HIV-1 transmission dynamics. METHODS: Plasma samples were obtained from 1,027 ART-naïve patients in Guangxi. Viral subtypes and DRMs were identified. Transmission network and related factors were also determined. RESULTS: A total of 1,025 eligible sequences were obtained from Qinzhou (65.8%) and Baise (34.2%) cities. The predominant HIV-1 genotype was CRF08_BC (45.0%), followed by CRF01_AE (40.9%). The overall prevalence of PDR was 8.3%, and resistance to NNRTI was the most common. Putative links with at least one other sequence were found in 543/1,025 (53.0%) sequences, forming 111 clusters (2–143 individuals). The most prevalent shared DRMs included V106I (45.35%), V179D (15.1%), and V179E (15.1%). Clusters related to shared DRMs were more frequent and larger in CRF08_BC. The prevalence of shared DRMs increased with time, while the proportion of PDR gradually decreased. Age > 50 years was associated with clustering. Subtype CRF08_BC was more likely to have DRMs, PDR propagation, and DRM sharing. CONCLUSION: PDR prevalence is moderate in this region. The association between PDR and subtype CRF08_BC suggested that DRMs spreading from injection drug users (IDUs) to heterosexuals (HETs) might be the major source of PDR in this region. Our findings highlight the significance of continuous surveillance of PDR.
format Online
Article
Text
id pubmed-8460771
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84607712021-09-25 Using Molecular Transmission Networks to Reveal the Epidemic of Pretreatment HIV-1 Drug Resistance in Guangxi, China Zhang, Fei Liang, Bingyu Liang, Xu Lin, Zhaosen Yang, Yuan Liang, Na Yang, Yao Liang, Huayue Jiang, Jiaxiao Huang, Jiegang Huang, Rongye Zhong, Shanmei Qin, Cai Jiang, Junjun Ye, Li Liang, Hao Front Genet Genetics INTRODUCTION: Pretreatment drug resistance (PDR) is becoming an obstacle to the success of ART. This study investigated the prevalence of PDR and the transmission clusters (TCs) of drug resistance mutations (DRMs) in two cities where drug abuse used to be high to describe the local HIV-1 transmission dynamics. METHODS: Plasma samples were obtained from 1,027 ART-naïve patients in Guangxi. Viral subtypes and DRMs were identified. Transmission network and related factors were also determined. RESULTS: A total of 1,025 eligible sequences were obtained from Qinzhou (65.8%) and Baise (34.2%) cities. The predominant HIV-1 genotype was CRF08_BC (45.0%), followed by CRF01_AE (40.9%). The overall prevalence of PDR was 8.3%, and resistance to NNRTI was the most common. Putative links with at least one other sequence were found in 543/1,025 (53.0%) sequences, forming 111 clusters (2–143 individuals). The most prevalent shared DRMs included V106I (45.35%), V179D (15.1%), and V179E (15.1%). Clusters related to shared DRMs were more frequent and larger in CRF08_BC. The prevalence of shared DRMs increased with time, while the proportion of PDR gradually decreased. Age > 50 years was associated with clustering. Subtype CRF08_BC was more likely to have DRMs, PDR propagation, and DRM sharing. CONCLUSION: PDR prevalence is moderate in this region. The association between PDR and subtype CRF08_BC suggested that DRMs spreading from injection drug users (IDUs) to heterosexuals (HETs) might be the major source of PDR in this region. Our findings highlight the significance of continuous surveillance of PDR. Frontiers Media S.A. 2021-09-10 /pmc/articles/PMC8460771/ /pubmed/34567064 http://dx.doi.org/10.3389/fgene.2021.688292 Text en Copyright © 2021 Zhang, Liang, Liang, Lin, Yang, Liang, Yang, Liang, Jiang, Huang, Huang, Zhong, Qin, Jiang, Ye and Liang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Zhang, Fei
Liang, Bingyu
Liang, Xu
Lin, Zhaosen
Yang, Yuan
Liang, Na
Yang, Yao
Liang, Huayue
Jiang, Jiaxiao
Huang, Jiegang
Huang, Rongye
Zhong, Shanmei
Qin, Cai
Jiang, Junjun
Ye, Li
Liang, Hao
Using Molecular Transmission Networks to Reveal the Epidemic of Pretreatment HIV-1 Drug Resistance in Guangxi, China
title Using Molecular Transmission Networks to Reveal the Epidemic of Pretreatment HIV-1 Drug Resistance in Guangxi, China
title_full Using Molecular Transmission Networks to Reveal the Epidemic of Pretreatment HIV-1 Drug Resistance in Guangxi, China
title_fullStr Using Molecular Transmission Networks to Reveal the Epidemic of Pretreatment HIV-1 Drug Resistance in Guangxi, China
title_full_unstemmed Using Molecular Transmission Networks to Reveal the Epidemic of Pretreatment HIV-1 Drug Resistance in Guangxi, China
title_short Using Molecular Transmission Networks to Reveal the Epidemic of Pretreatment HIV-1 Drug Resistance in Guangxi, China
title_sort using molecular transmission networks to reveal the epidemic of pretreatment hiv-1 drug resistance in guangxi, china
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460771/
https://www.ncbi.nlm.nih.gov/pubmed/34567064
http://dx.doi.org/10.3389/fgene.2021.688292
work_keys_str_mv AT zhangfei usingmoleculartransmissionnetworkstorevealtheepidemicofpretreatmenthiv1drugresistanceinguangxichina
AT liangbingyu usingmoleculartransmissionnetworkstorevealtheepidemicofpretreatmenthiv1drugresistanceinguangxichina
AT liangxu usingmoleculartransmissionnetworkstorevealtheepidemicofpretreatmenthiv1drugresistanceinguangxichina
AT linzhaosen usingmoleculartransmissionnetworkstorevealtheepidemicofpretreatmenthiv1drugresistanceinguangxichina
AT yangyuan usingmoleculartransmissionnetworkstorevealtheepidemicofpretreatmenthiv1drugresistanceinguangxichina
AT liangna usingmoleculartransmissionnetworkstorevealtheepidemicofpretreatmenthiv1drugresistanceinguangxichina
AT yangyao usingmoleculartransmissionnetworkstorevealtheepidemicofpretreatmenthiv1drugresistanceinguangxichina
AT lianghuayue usingmoleculartransmissionnetworkstorevealtheepidemicofpretreatmenthiv1drugresistanceinguangxichina
AT jiangjiaxiao usingmoleculartransmissionnetworkstorevealtheepidemicofpretreatmenthiv1drugresistanceinguangxichina
AT huangjiegang usingmoleculartransmissionnetworkstorevealtheepidemicofpretreatmenthiv1drugresistanceinguangxichina
AT huangrongye usingmoleculartransmissionnetworkstorevealtheepidemicofpretreatmenthiv1drugresistanceinguangxichina
AT zhongshanmei usingmoleculartransmissionnetworkstorevealtheepidemicofpretreatmenthiv1drugresistanceinguangxichina
AT qincai usingmoleculartransmissionnetworkstorevealtheepidemicofpretreatmenthiv1drugresistanceinguangxichina
AT jiangjunjun usingmoleculartransmissionnetworkstorevealtheepidemicofpretreatmenthiv1drugresistanceinguangxichina
AT yeli usingmoleculartransmissionnetworkstorevealtheepidemicofpretreatmenthiv1drugresistanceinguangxichina
AT lianghao usingmoleculartransmissionnetworkstorevealtheepidemicofpretreatmenthiv1drugresistanceinguangxichina